Race Oncology (RAC) Stock Overview
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
RAC Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Race Oncology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.13 |
| 52 Week High | AU$3.57 |
| 52 Week Low | AU$0.92 |
| Beta | 1.94 |
| 1 Month Change | 163.03% |
| 3 Month Change | 160.83% |
| 1 Year Change | 76.34% |
| 3 Year Change | 63.45% |
| 5 Year Change | 309.15% |
| Change since IPO | 1,081.13% |
Recent News & Updates
Recent updates
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?
Aug 26
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully
May 10We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate
Jan 23Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 05Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth
Jun 20We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow
Feb 17Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 14Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Apr 01We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely
Apr 05What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?
Mar 01How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?
Jan 07
Shareholder Returns
| RAC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 1.0% | -1.8% | 0.2% |
| 1Y | 76.3% | -29.7% | 6.9% |
Return vs Industry: RAC exceeded the Australian Biotechs industry which returned -29.7% over the past year.
Return vs Market: RAC exceeded the Australian Market which returned 6.9% over the past year.
Price Volatility
| RAC volatility | |
|---|---|
| RAC Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 19.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RAC's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: RAC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.raceoncology.com |
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.
Race Oncology Limited Fundamentals Summary
| RAC fundamental statistics | |
|---|---|
| Market cap | AU$544.00m |
| Earnings (TTM) | -AU$4.79m |
| Revenue (TTM) | AU$6.04m |
Is RAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAC income statement (TTM) | |
|---|---|
| Revenue | AU$6.04m |
| Cost of Revenue | AU$635.21k |
| Gross Profit | AU$5.41m |
| Other Expenses | AU$10.20m |
| Earnings | -AU$4.79m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 89.49% |
| Net Profit Margin | -79.22% |
| Debt/Equity Ratio | 0% |
How did RAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/27 15:26 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Race Oncology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Independent Investment Research (Aust.) Pty Ltd |
| Chris Kallos | MST Financial Services Pty Limited |